These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 30250466)

  • 1. Treating Influenza Infection, From Now and Into the Future.
    Davidson S
    Front Immunol; 2018; 9():1946. PubMed ID: 30250466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody dynamics in Japanese paediatric patients with influenza A infection treated with neuraminidase inhibitors in a randomised trial.
    Hirotsu N; Saisho Y; Hasegawa T; Kitano M; Shishido T
    Sci Rep; 2019 Aug; 9(1):11891. PubMed ID: 31417163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Antiviral Resistance in Influenza.
    Li TC; Chan MC; Lee N
    Viruses; 2015 Sep; 7(9):4929-44. PubMed ID: 26389935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing antiviral therapy for influenza: understanding the evidence.
    Ison MG
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):417-25. PubMed ID: 25695406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors.
    Liao LE; Kowal S; Cardenas DA; Beauchemin CAA
    PLoS One; 2017; 12(8):e0183621. PubMed ID: 28837615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-influenza drugs and neuraminidase inhibitors.
    Roberts NA
    Prog Drug Res; 2001; 56():195-237. PubMed ID: 11417114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.
    Oxford J; Balasingam S; Lambkin R
    J Antimicrob Chemother; 2004 Feb; 53(2):133-6. PubMed ID: 14688047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
    Meijer A; Rebelo-de-Andrade H; Correia V; Besselaar T; Drager-Dayal R; Fry A; Gregory V; Gubareva L; Kageyama T; Lackenby A; Lo J; Odagiri T; Pereyaslov D; Siqueira MM; Takashita E; Tashiro M; Wang D; Wong S; Zhang W; Daniels RS; Hurt AC
    Antiviral Res; 2014 Oct; 110():31-41. PubMed ID: 25043638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitor resistance in influenza: a clinical perspective.
    Lee N; Hurt AC
    Curr Opin Infect Dis; 2018 Dec; 31(6):520-526. PubMed ID: 30299356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
    Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
    Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza virus resistance to neuraminidase inhibitors.
    Samson M; Pizzorno A; Abed Y; Boivin G
    Antiviral Res; 2013 May; 98(2):174-85. PubMed ID: 23523943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zanamivir: a rational approach to influenza B.
    Penn CR; Osterhaus A
    Scand J Infect Dis; 2001; 33(1):33-40. PubMed ID: 11234975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza and antiviral resistance: an overview.
    Lampejo T
    Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1201-1208. PubMed ID: 32056049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of sialidase activity as a therapeutic approach.
    Glanz VY; Myasoedova VA; Grechko AV; Orekhov AN
    Drug Des Devel Ther; 2018; 12():3431-3437. PubMed ID: 30349196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-influenza drugs and neuraminidase inhibitors.
    Roberts NA
    Prog Drug Res; 2001; Spec No():35-77. PubMed ID: 11548210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance.
    Han J; Perez J; Schafer A; Cheng H; Peet N; Rong L; Manicassamy B
    Curr Med Chem; 2018; 25(38):5115-5127. PubMed ID: 28933281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
    Baek YH; Song MS; Lee EY; Kim YI; Kim EH; Park SJ; Park KJ; Kwon HI; Pascua PN; Lim GJ; Kim S; Yoon SW; Kim MH; Webby RJ; Choi YK
    J Virol; 2015 Jan; 89(1):287-99. PubMed ID: 25320319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging antiviral therapies and drugs for the treatment of influenza.
    Wang J; Sun Y; Liu S
    Expert Opin Emerg Drugs; 2022 Dec; 27(4):389-403. PubMed ID: 36396398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Perspectives of antiviral drugs used on influenza].
    Wang YM; Cao B
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Aug; 39(8):1051-1059. PubMed ID: 30180427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor.
    Eichelberger MC; Prince GA; Ottolini MG
    Virology; 2004 May; 322(2):300-7. PubMed ID: 15110527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.